Inhaled Nitric Oxide Market by Application (Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Malaria Treatment), End-Users (Clinic, Hospital) - Global Forecast 2024-2030

Inhaled Nitric Oxide Market by Application (Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Malaria Treatment), End-Users (Clinic, Hospital) - Global Forecast 2024-2030

The Inhaled Nitric Oxide Market size was estimated at USD 778.21 million in 2023 and expected to reach USD 821.09 million in 2024, at a CAGR 5.83% to reach USD 1,157.38 million by 2030.

Inhaled nitric oxide (iNO) is a pulmonary vasodilator used in intensive care medicine to manage acute and chronic pulmonary disorders. It is administered through inhalation, directly reaching the lungs and improving oxygenation by dilating pulmonary blood vessels without significantly affecting blood pressure in other body parts. Its primary use is in neonatal and pediatric populations for conditions including persistent pulmonary hypertension of the newborn (PPHN) and acute respiratory distress syndrome (ARDS). The rising incidence of neonatal conditions requiring iNO therapy, such as PPHN, and an increase in cases of ARDS have significantly propelled the need for inhaled nitric oxide. Additionally, technological advancements enabling portable NO delivery systems have expanded the applicability of the treatments in different care settings, including home care. The ongoing research and potential new indications for iNO in adults with pulmonary diseases offer growth avenues for the market. However, the high cost and stringent regulatory requirements for approval associated with inhaled nitric oxide pose significant barriers to the entry of new players and can limit market growth. Moreover, the exploration of new therapeutic indications and innovations in administration technology that are expected to reduce costs and improve accessibility are promising areas for the inhaled nitric oxide market.

Regional Insights

In the Americas, particularly in the United States and Canada, the adoption of inhaled nitric oxide is increasing rapidly owing to the high prevalence of respiratory diseases and the strong presence of healthcare facilities with advanced technological setups. The FDA's proactive role in approving inhaled nitric oxide products for various medical conditions, including pulmonary arterial hypertension and hypoxic respiratory failure, has bolstered the growth of the inhaled nitric oxide market. Moreover, major players in the pharmaceutical and medical device industries in this region are intensively involved in R&D activities, aiming to expand the application range of inhaled nitric oxide therapy. The EMEA region exhibits a dynamic market for inhaled nitric oxide, with Europe majorly contributing to adoption and innovation. The increasing incidence of neonatal conditions and respiratory diseases in this region has heightened the need for effective therapeutic solutions, including inhaled nitric oxide. Regulatory bodies in Europe, such as the European Medicines Agency (EMA), have laid down stringent guidelines and approval processes, ensuring the safety and efficacy of inhaled nitric oxide products. In the Middle East and Africa, the market is gradually expanding, primarily driven by healthcare infrastructure developments and growing awareness about advanced treatment modalities. The APAC region is witnessing the rapid adoption of inhaled nitric oxide therapies owing to rising healthcare expenditure, an increasing population base, and a growing number of preterm birth incidences. Countries such as China, Japan, and India are at the forefront of this adoption, driven by ongoing healthcare reforms, increasing investments in healthcare infrastructure, and rising awareness about innovative therapeutic options, including inhaled nitric oxide. Furthermore, the presence of a significant number of generic pharmaceutical manufacturers in this region offers cost-effective solutions, making inhaled nitric oxide therapy more accessible to a larger patient population.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Inhaled Nitric Oxide Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising incidents of respiratory disorders worldwide
    • Increase in neonatal intensive care facilities with growing healthcare expenditure
    • Market Restraints
      • High cost associated with treatments involving inhaled nitric oxide
      • Market Opportunities
        • Improvements in production and storage technologies of inhaled nitric oxide
        • Continuous research to boost the application of inhaled nitric oxide
        • Market Challenges
          • Stringent government regulations for inhaled nitric oxide usage
          • Market Segmentation Analysis
            • Application: Increasing incidences of chronic obstructive pulmonary disease
            • End-Users: Growing deployment of inhaled nitric oxide devices in hospitals for neonatal and intensive care units
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Inhaled Nitric Oxide Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Inhaled Nitric Oxide Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Vero Biotech Secures USD 65 Million Credit Facility for Nitric Oxide Delivery System
              
              Vero Biotech has secured a USD 65 million credit facility earmarked for the enhancement of its innovative nitric oxide delivery system. This strategic financial infusion is poised to revolutionize the administration of inhaled nitric oxide, a critical treatment for patients grappling with respiratory conditions. By leveraging this considerable investment, Vero Biotech aims to further refine its delivery technology, underscoring its commitment to advancing respiratory care and improving patient outcomes.
              
              Third Pole Doses First Patient in Trial with Nitric Oxide Delivery System
              
              Third Pole Therapeutics has initiated a pioneering early feasibility trial, marking a significant advancement in the treatment of pulmonary hypertension related to interstitial lung disease (PH-ILD) with the first patient being dosed with its innovative portable inhaled nitric oxide (iNO) delivery system, the eNOfit device. This multi-center trial (NCT05867914) aims to assess the safety and tolerability of the eNOfit device, which heralds new possibilities for ambulatory treatment.
              
              Mallinckrodt Announces FDA Clearance of the INOmax EVOLVE DS Delivery System and Approval of the INOmax (Nitric Oxide) Mini-Cylinder
              
              Mallinckrodt PLC announces the FDA clearance of its cutting-edge INOmax EVOLVE DS delivery system for administering INOmax (nitric oxide gas) for inhalation, marking a significant breakthrough in treating respiratory failure. This system is specifically designed for ventilated patients and ensures a consistent dose of nitric oxide throughout the breathing process by leveraging a unique injector module for precise synchronization and dosage.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Inhaled Nitric Oxide Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Inhaled Nitric Oxide Market, highlighting leading vendors and their innovative profiles. These include Air Liquide SA, Beyond Air, Inc., GE HealthCare Technologies, Inc., Getinge AB, Linde PLC, Mallinckrodt PLC, Matheson Tri-Gas, Inc. by Mitsubishi Chemical Group Corporation, Merck KGaA, NIOX Group PLC, Perma Pure LLC by Halma PLC, SOL Group, Third Pole, Inc., and VERO Biotech Inc..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Inhaled Nitric Oxide Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Application
              • Acute Respiratory Distress Syndrome
              • Chronic Obstructive Pulmonary Disease
              • Malaria Treatment
              • Neonatal Respiratory Treatment
              • Tuberculosis Treatment
              • End-Users
                • Clinic
                • Hospital
                • Region
                  • Americas
                    • Argentina
                    • Brazil
                    • Canada
                    • Mexico
                    • United States
                      • California
                      • Florida
                      • Illinois
                      • New York
                      • Ohio
                      • Pennsylvania
                      • Texas
                      • Asia-Pacific
                        • Australia
                        • China
                        • India
                        • Indonesia
                        • Japan
                        • Malaysia
                        • Philippines
                        • Singapore
                        • South Korea
                        • Taiwan
                        • Thailand
                        • Vietnam
                        • Europe, Middle East & Africa
                          • Denmark
                          • Egypt
                          • Finland
                          • France
                          • Germany
                          • Israel
                          • Italy
                          • Netherlands
                          • Nigeria
                          • Norway
                          • Poland
                          • Qatar
                          • Russia
                          • Saudi Arabia
                          • South Africa
                          • Spain
                          • Sweden
                          • Switzerland
                          • Turkey
                          • United Arab Emirates
                          • United Kingdom
                          
                          
                          Please Note: PDF & Excel + Online Access - 1 Year